Treatment of myelodysplastic syndromes with 5-azacytidine.

Gryn, Jeffrey; Zeigler, Zella R; Shadduck, Richard K; Lister, John; Raymond, Jane M; Sbeitan, Ibrahim; Srodes, Charles; Meisner, Dennis; Evans, Cynthia

Gryn, Jeffrey; Zeigler, Zella R; Shadduck, Richard K; Lister, John; Raymond, Jane M; Sbeitan, Ibrahim; Srodes, Charles; Meisner, Dennis; Evans, Cynthia.

Affiliation

Gryn J; Western Pennsylvania Cancer Institute, 4800 Friendship Avenue, Suite 2303, Pittsburgh, PA 15224, USA. jgryn@wpahs.org

Leuk Res ; 26(10): 893-7, 2002 Oct.

Article in En | MEDLINE | ID: mdl-12163049

Subject(s)

Azacitidine/administration & dosage; Myelodysplastic Syndromes/drug therapy; Adult; Aged; Aged, 80 and over; Anemia/drug therapy; Anemia/etiology; Azacitidine/toxicity; Blood Transfusion/statistics & numerical data; Female; Humans; Leukocytes; Male; Middle Aged; Myelodysplastic Syndromes/blood; Myelodysplastic Syndromes/complications; Prognosis; Retrospective Studies; Thrombocytopenia/drug therapy; Thrombocytopenia/etiology; Treatment Outcome

Search on Google

Add to My VHL

XML

PubMed Links

Database: MEDLINE Main subject: Azacitidine / Myelodysplastic Syndromes Type of study: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Leuk Res Year: 2002 Type: Article Affiliation country: United States

Search on Google

Add to My VHL

XML

PubMed Links